Summary of Alumis Conference Call Company Overview - Company: Alumis - Lead Candidate: Nvudusitinib, a next-generation TYK2 inhibitor - Focus: Treatment of moderate to severe plaque psoriasis and potential applications in other immune-mediated diseases Key Points from the Call Clinical Results - Phase 3 Results: Positive outcomes for Nvudusitinib, exceeding Phase 2 results with statistically significant efficacy on primary and secondary endpoints [4][5] - Efficacy Metrics: - 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at week 16 [12] - Approximately 65% achieved PASI 90 and over 40% achieved PASI 100 at week 24 [12] - Safety Profile: Favorable safety and tolerability consistent with Phase 2 data, with most adverse events being mild to moderate [13] Market Opportunity - Psoriasis Market: Expected to reach $40 billion by 2030, with many patients currently underserved [6] - Treatment Landscape: Less than 20% of patients receive systemic treatment, and only 8% are treated with high-efficacy drugs [21] - Patient Preferences: 75% of patients prefer oral therapies over biologics, highlighting the demand for convenient treatment options [24] Future Developments - NDA Filing: Anticipated in the second half of 2026, pending data from the randomized withdrawal portion of the Phase 3 trial [37] - Additional Trials: Plans for a pivotal Phase 2b trial in systemic lupus erythematosus (SLE) with top-line data expected in Q3 2026 [6][28] - Pipeline Expansion: Development of A005, a CNS-penetrant TYK2 inhibitor, with a Phase 2 trial in multiple sclerosis planned for the first half of the year [27] Competitive Landscape - Comparison with Competitors: Nvudusitinib shows competitive efficacy compared to other oral therapies, including Icotrokinra and Apremilast [32][50] - Mechanism of Action: TYK2 inhibition may provide additional benefits beyond IL-23 and IL-17 pathways, particularly in itch reduction [51] Strategic Insights - Market Positioning: Alumis aims to position Nvudusitinib as a leading oral therapy for psoriasis, addressing significant unmet needs in the market [20][25] - Partnership Considerations: The company is evaluating strategic partnerships to maximize the asset's value, particularly in light of its broad potential across multiple indications [54] Additional Considerations - Patient-Reported Outcomes: Improvements in quality of life and itch were noted, which are critical factors for patient satisfaction [5][19] - Regulatory Strategy: Ongoing discussions with the FDA regarding the NDA filing and statistical analysis plans [38] Conclusion - Outlook for 2026: Alumis anticipates significant value inflection with the advancement of Nvudusitinib and its broader pipeline, aiming to address the substantial unmet needs in the treatment of psoriasis and other immune-mediated diseases [77]
Alumis (NasdaqGS:ALMS) Update / Briefing Transcript